We would like to thank Reviewers for taking the necessary time and effort to review the manuscript. We sincerely appreciate all your valuable comments and suggestions, which helped us in improving the quality of the manuscript.

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Major revision

Specific Comments to Authors: The current study is a meta-analysis that aims to assess treatment of COVID-19 with bamlanivimab. The study is interesting and may attract lots of attention. However, there are issues to address.

1. Abstract/methods. Keywords used for the search of literature should be indicated. The use of bamlanivimab alone should be indicated.

Author's response: Thank you for your valuable point. It is revised.

2. All abbreviations in the Abstract (and in the text – first time used) should be deciphered.

ICU , ROB … etc

Author's response: Thank you for your valuable point. It is revised.

3. Abstract/ tables: indicate the age group of assessed patients.

Author's response: Thank you for your valuable point. It is revised.

4. Tables; a median or mean age of patients should be indicated. Male% should be also indicated. If studies indicate dhte procentage of comorbidies/co-infections – it should be also discussed and indicated in a table.

Author's response: Thank you for your valuable point. It is revised.

5. Adverse events should be described in more details.

Author's response: Thank you for your valuable point. It is revised.

6. Authors did not mention the "long COVID" and associated long term debilitating symptoms. It is necessary to add this to the Discussion section (see this

https://pubmed.ncbi.nlm.nih.gov/36100326/)

Author's response: Thank you for your valuable point. We have discussed the post COVID-19 condition and its connection to the effective treatments for COVID-19.

7. Indicate which SARS strains developed resistance to bamlanivimab.

Author's response: Thank you for your valuable point. It is revised.

8. Another missing point: co-infection with other agents? Effect of different SARS-CoV-2 strains? (See Beeraka et al., 2022 https://pubmed.ncbi.nlm.nih.gov/35416390/. It has to be discussed.

Author's response: Thank you for your valuable point. We investigated the efficacy of bamlanivimab alone, a monoclonal antibody for COVID-19. Beeraka'S study has discussed COVID-19 vaccines against strains of SARS-CoV-2. The findings of this study might not be related to our result. Moreover, most included studies in our research did not report COVID-19 vaccination status.

9. Conclusions/future perspectives should indicate a direction for future assessments, including long COVID and assessment of the risk groups aged population), co-infections, development of resistance etc.

Author's response: Thank you for your valuable point. It is revised.

I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Virology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before its final acceptance, please provide and upload the following important documents:

Biostatistics Review Certificate, a statement affirming that the statistical review of the study was performed by a biomedical statistician;

PRISMA 2009 Checklist, an important document related to manuscript writing of systematic review, meta-analysis, and scientometrics research.

Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1 Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...".

Please provide the original figure documents.

Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the

author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2023.

Authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content.

JOURNAL EDITORIAL BOARD'S REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 88660

Title: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Journal Editor-in-Chief/Associate Editor/Editorial Board Member: Kai Wang

Country/Territory: China

Editorial Director: Jia-Ping Yan

Date accepted review: 2023-12-06 14:22

Date reviewed: 2023-12-06 14:23

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	[Y] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of	[ ] Rejection
[ ] Grade D: Fair	language polishing	[ ] Minor revision
[ ] Grade E: Poor	[ ] Grade D: Rejected	[ ] Major revision

JOURNAL EDITORIAL BOARD COMMENTS TO AUTHORS

The present meta-analysis was overall well designed and conducted. The results are of clinical importance.

Reply: Thanks for your comments.

JOURNAL EDITORIAL BOARD'S REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 88660

Title: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Journal Editor-in-Chief/Associate Editor/Editorial Board Member: Shuai Gao

Country/Territory: China

Editorial Director: Jia-Ping Yan

Date accepted review: 2023-12-09 14:22

Date reviewed: 2023-12-09 14:22

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION
[　] Grade A: Excellent	[　] Grade A: Priority publishing	[　] Accept
[　] Grade B: Very good	[　] Grade B: Minor language polishing	[　] High priority for publication
[Y] Grade C: Good	[Y] Grade C: A great deal of	[　] Rejection
[　] Grade D: Fair	language polishing	[Y] Minor revision
[　] Grade E: Poor	[　] Grade D: Rejected	[　] Major revision

JOURNAL EDITORIAL BOARD COMMENTS TO AUTHORS

In this manuscript, the authors presented a systematic review and meta-analysis on the efficacy and safety of bamlanivimab in the treatment of coronavirus disease 2019 (COVID-19). A significant difference was observed between the bamlanivimab and standard of care/placebo groups in terms of mortality rate, hospitalization rate, and emergency department visits. While the two groups exhibited no significant difference in terms of intensive care unit admission. These results suggested that bamlanivimab might be effective and safe for the treatment of COVID-19. Overall, the manuscript is well prepared. The language should be edited carefully.

Reply: Thanks for your comments, we had edited the language carefully.